Further clinical studies of trimethylpurin-6-ylammonium chloride (NSC-51095) in malignant disease with special emphasis on cancer of urinary bladder.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000963:Antimetabolites / Q000009:adverse effects / Q000627:therapeutic use*; D001984:Bronchial Neoplasms / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D004938:Esophageal Neoplasms / Q000188:drug therapy; D005069:Evaluation Studies as Topic; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy; D006390:Hemangioendothelioma / Q000188:drug therapy; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy; D007680:Kidney Neoplasms / Q000188:drug therapy; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D007890:Leiomyosarcoma / Q000188:drug therapy; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000188:drug therapy; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D011687:Purines / Q000009:adverse effects / Q000627:therapeutic use*; D000644:Quaternary Ammonium Compounds / Q000009:adverse effects / Q000627:therapeutic use; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014565:Urogenital Neoplasms / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
D000963:Antimetabolites; D011687:Purines; D000644:Quaternary Ammonium Compounds